Treatment-wise, the technological innovations in insulin therapy (such as smart insulin pens and insulin pumps with automatic insulin infusion) play a pivotal role, nowadays, in achieving and maintaining satisfying glycemic control with a lower risk of micro- or macroangiopathic complications, in children with T1DM and DS. The gene discussed is INS; the disease is type 1 diabetes mellitus.